mani
viral
pathogen
caus
infecti
diseas
human
highli
restrict
speci
tropism
make
studi
pathogenesi
develop
clinic
therapi
difficult
improv
human
mous
model
past
year
greatli
facilit
research
abil
studi
host
respons
viral
infect
cost
effect
ethic
manner
hiv
hepatotrop
virus
middl
east
respiratori
syndrom
coronaviru
human
mice
led
identif
factor
crucial
viral
life
cycl
outlet
test
candid
therapi
improv
analysi
human
immun
respons
infect
tackl
new
old
virus
emerg
human
mice
continu
indispens
tool
virus
make
stagger
contribut
morbid
mortal
human
popul
industri
develop
countri
least
million
peopl
chronic
infect
hepat
b
hbv
c
virus
hcv
place
risk
develop
sever
liver
diseas
million
individu
infect
hiv
lead
million
aidsrel
death
everi
year
approxim
million
peopl
contract
dengu
viru
denv
annual
almost
million
present
clinic
symptom
global
popul
infect
herp
simplex
virus
hsv
result
n
orolabi
genit
lesion
human
cytomegaloviru
hcmv
persist
infect
world
lifethreaten
newborn
immunocompromis
individu
mani
virus
caus
diseas
human
narrow
host
rang
often
limit
human
close
relat
nonhuman
primat
nhp
creat
challeng
studi
pathogenesi
humantrop
virus
experi
nhp
hamper
logist
financi
ethic
concern
creat
press
need
tractabl
small
anim
model
studi
exist
emerg
viral
diseas
last
decad
human
mice
emerg
solut
problem
human
mice
gener
express
human
gene
whose
product
need
viral
infect
tabl
entri
factor
xenotransplant
hematopoiet
stem
cell
creat
human
immun
system
mice
known
andor
human
tissu
figur
paper
highlight
recent
progress
challeng
studi
viral
pathogenesi
human
mice
discuss
four
group
humantrop
virus
hiv
denv
herpesvirus
hepat
virusesa
exampl
diseas
specif
type
human
mice
still
enabl
experiment
platform
use
exampl
provid
gener
outlook
human
mice
adapt
refin
genet
host
adapt
andor
coengraft
multipl
tissu
facilit
analysi
viral
infect
alon
million
peopl
worldwid
die
aid
million
cite
live
hiv
besid
human
chimpanze
readili
suscept
hiv
sinc
usual
progress
aid
gain
traction
hiv
anim
model
search
altern
shown
smaller
nhp
specif
rhesu
macaqu
suscept
simian
immunodefici
viru
siv
lead
aidslik
symptom
improv
util
model
chimer
virus
close
resembl
name
simianhuman
immunodefici
viru
shiv
simiantrop
hiv
sthiv
gener
despit
intens
effort
far
becom
possibl
genet
overcom
speci
barrier
recapitul
hiv
lifecycl
small
anim
model
advanc
made
primarili
focus
establish
hiv
uptak
mice
sinc
hiv
lymphotrop
viru
primarili
infect
cell
engraft
human
immun
system
compon
prove
viabl
approach
establish
hiv
infect
small
anim
model
earli
model
pioneer
mccune
colleagu
base
engraft
xenorecipi
human
fetal
thymic
lymph
node
implant
demonstr
acut
infect
human
lymphoid
organ
follow
human
mice
improv
xenorecipi
strain
human
protocol
extens
review
human
immun
system
mice
deepen
knowledg
hiv
viral
transmiss
immun
respons
hiv
efficaci
novel
therapeut
intervent
abil
cell
form
latent
reservoir
especi
challeng
complet
cure
individu
viru
recent
sever
group
shown
latenc
observ
human
mous
model
mice
made
possibl
model
vivo
exampl
treatment
use
broadli
neutral
antibodi
combin
induc
prevent
viral
rebound
follow
remov
antiretrovir
hinder
transmiss
vector
immunoprophylaxi
shown
promis
way
obstruct
intraven
mucos
transmiss
hiv
human
mice
latter
primari
rout
individu
becom
infect
vivo
model
mucos
hiv
transmiss
physiolog
relev
provid
venu
test
antivir
therapi
immun
respons
mice
suboptim
varieti
incompat
mous
human
immun
system
nonetheless
shown
particular
version
mice
socal
bonemarrow
liver
thymu
blt
mice
dynam
interplay
hivspecif
cellular
immun
viral
escap
immun
pressur
accur
model
dengu
mosquitoborn
diseas
caus
denv
positivesens
singlestrand
rna
viru
belong
famili
flavivirida
four
genet
antigen
distinct
serotyp
describ
annual
caus
million
infect
rang
sever
complet
asymptomat
lethal
hemorrhag
fever
shock
syndrom
dhf
dss
respect
sinc
vaccin
still
exist
studi
immun
respons
denv
especi
import
individu
previou
immun
suscept
develop
dhf
dss
murin
xenorecipi
strain
express
inject
human
bloodform
stem
cell
demonstr
improv
immun
respons
tissuecultur
deriv
denv
especi
assess
human
tcell
respons
denv
acut
infect
addit
shown
viremia
suppress
administr
directact
antivir
daa
human
mice
display
symptom
similar
human
follow
infect
clinic
denv
isol
pave
way
creat
test
daa
could
util
treat
denv
howev
prime
denvspecif
b
cell
respons
occur
level
suffici
robust
exist
model
pose
challeng
untangl
mechan
dhfdss
much
higher
individu
secondari
heterolog
denv
infect
light
also
shed
identifi
cell
target
denv
past
research
human
mice
conclud
cell
infect
denv
two
group
recent
observ
evid
contrari
final
sinc
denv
mosquitoborn
understand
transmiss
host
vector
vice
versa
import
examin
viral
spread
popul
prevent
largescal
outbreak
thu
examin
first
time
human
immun
respons
human
mice
follow
denv
infect
mosquito
bite
encourag
step
nine
hhv
preval
establish
longlast
latent
infect
lead
skin
lesion
epilepsi
cancer
autoimmun
diseas
review
see
epstein
barr
viru
ebv
widespread
link
human
tumor
origin
lymphocyt
epitheli
cell
b
cell
ebv
infect
studi
human
mice
differ
stage
latent
lytic
viral
life
cycl
observ
cell
ebvassoci
malign
also
studi
mice
viral
mutant
lack
ebv
latent
nuclear
antigen
led
format
larg
b
cell
lymphoma
mice
research
strain
provid
evid
variou
antigen
regul
express
chemokin
lead
reduc
cell
action
ebvassoci
hemophagocyt
lymphohistiocytosi
patholog
highli
similar
seen
human
eros
arthriti
observ
human
mice
final
mice
also
platform
examin
role
innat
immun
final
immunocompromis
mice
human
skin
transplant
util
studi
hbv
hcv
togeth
infect
million
individu
worldwid
caus
liver
cirrhosi
fibrosi
hepatocellular
carcinoma
left
untreat
two
virus
robustli
infect
chimpanze
human
absenc
permiss
mous
model
numer
transgen
strain
express
individu
combin
hcv
gene
product
develop
studi
hbv
hcvinduc
liver
diseas
hcv
indepth
review
exist
human
mous
model
virus
hbv
transgen
mice
contribut
substanti
understand
mani
aspect
hbv
biolog
immunobiolog
pathogenesi
review
contrast
report
histopatholog
hcv
protein
transgen
mice
differ
vastli
depend
express
hcv
gene
product
mous
background
differ
promot
use
express
viral
protein
util
lessen
bona
fide
infect
model
patholog
process
develop
absenc
inflammatori
milieu
establish
chronic
infect
studi
hbv
hcv
infect
mice
human
mous
liver
xenoengraft
permiss
human
primari
hepatocyt
explor
commonli
use
xenorecipi
share
common
featur
immunodefici
prevent
xenograft
reject
often
suffer
endogen
liver
injuri
promot
hepatocyt
prolifer
provid
human
donor
cell
competit
growth
advantag
mous
hepatocyt
develop
mous
could
engraft
primari
human
hepatocyt
success
infect
hbv
also
hcv
improv
robust
throughput
sever
immunodefici
liver
injuri
model
includ
fumaryl
acetoacet
hydrolas
defici
mice
fah
mupupa
gener
mice
engraft
high
level
human
hepatocyt
subsequ
becom
suscept
hbv
hcv
infect
human
liver
chimer
mice
critic
tool
studi
hbv
hcv
hdv
infect
also
serv
import
tool
preclin
assess
efficaci
novel
therapeut
howev
hbv
hcv
pathogenesi
human
adapt
immun
respons
vaccin
develop
studi
mous
model
harbor
human
liver
graft
function
human
immun
system
sever
group
report
dual
engraft
compon
human
immun
system
match
human
liver
achiev
singl
recipi
infect
hbv
hcv
use
human
mice
infecti
diseas
research
provid
forum
studi
virus
previous
unavail
due
speci
tropism
mani
type
human
mice
avail
research
continu
improv
expand
upon
model
research
discuss
provid
invalu
lesson
handl
emerg
viral
threat
exemplifi
quick
develop
human
mous
studi
middl
eastern
respiratori
syndrom
mer
lung
xenotransplant
model
emerg
nipah
viru
virus
continu
evolv
adapt
new
host
human
mice
indispens
tool
studi
pathogenesi
increas
likelihood
develop
efficaci
therapeut
cell
toler
respons
hbcag
liver
diseas
observ
hbvdna
high
viral
particl
product
figur
human
mice
studi
viral
pathogenesi
direct
cytopath
effect
viru
particular
tissu
studi
mice
engraft
singl
human
tissu
skin
engraft
util
studi
kshv
mice
exhibit
develop
skin
lesion
latent
infect
cell
alter
morpholog
similarli
vzv
human
mice
lesion
necrosi
multipl
skin
layer
respiratori
virus
nipah
viru
studi
mice
follow
engraft
human
fetal
lung
tissu
result
viral
infect
high
titer
specif
lung
follow
human
liver
engraft
mice
suscept
infect
hcv
hbv
lymphotrop
virus
ebv
studi
human
immun
system
mice
howev
mice
engraft
human
tissu
also
proven
util
studi
human
immun
respons
exhibit
viral
infect
analyz
infect
human
blt
mice
studi
observ
cell
respons
highli
similar
specif
kinet
magnitud
observ
human
rapid
appear
viral
escap
mutat
host
immun
respons
also
seen
human
underscor
util
human
blt
mice
studi
humanspecif
immunopatholog
pathogen
hunsg
mice
infect
ebv
found
develop
highli
aggress
tumor
find
connect
well
clinic
sampl
aggress
lymphoma
associ
mutat
work
human
mice
provid
novel
evid
might
first
exampl
virusencod
tumor
supressor
use
mice
diminish
antivir
immun
also
stabli
express
minim
human
factor
human
ocln
viral
uptak
murin
cell
studi
first
reproduc
entir
hcv
life
cycl
mice
inherit
suscept
hcv
signific
improv
upon
previou
xenotranspl
mous
model
allow
higher
throughput
work
decreas
variabl
experi
paper
identifi
first
hbv
hdv
rceptor
sodium
taurochol
cotransport
polypeptid
ntcp
use
tandem
affin
purif
mass
spectrometri
find
greatli
enhanc
research
abil
creat
vitro
platform
smallanim
model
studi
two
virus
follow
transduct
mice
recombin
nonrepl
adenoviru
express
human
receptor
mer
mice
success
infect
merscov
develop
pneumonia
quick
timelin
week
creat
model
promis
approach
rapid
studi
emerg
pathogen
first
human
lung
xenograft
model
mice
made
success
infect
nipah
viru
replic
high
titer
lung
promis
physiolog
relev
approach
studi
pathogenesi
respiratori
virus
context
human
lung
microenviron
